Insider Selling: Claudius Llc Sells 4,200 Shares of Acura Pharmaceuticals Stock (ACUR)
Acura Pharmaceuticals (NASDAQ:ACUR) major shareholder Claudius Llc unloaded 4,200 shares of Acura Pharmaceuticals stock on the open market in a transaction dated Thursday, October 10th. The stock was sold at an average price of $2.05, for a total transaction of $8,610.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of Acura Pharmaceuticals (NASDAQ:ACUR) traded down 3.19% on Friday, hitting $1.82. 459,694 shares of the company’s stock traded hands. Acura Pharmaceuticals has a 52-week low of $1.06 and a 52-week high of $4.50. The stock’s 50-day moving average is $1.63 and its 200-day moving average is $2.00. The company’s market cap is $84.6 million.
Acura Pharmaceuticals (NASDAQ:ACUR) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.07) earnings per share (EPS) for the quarter. Analysts expect that Acura Pharmaceuticals will post $-0.29 EPS for the current fiscal year.
A number of research firms have recently commented on ACUR. Analysts at MLV Capital cut their price target on shares of Acura Pharmaceuticals from $4.00 to $2.00 in a research note to investors on Thursday, August 29th. They now have a “buy” rating on the stock.
Acura Pharmaceuticals, Inc, is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.